# Query Results

**Query:** revenue models of IRG

**Timestamp:** 20251020_030001

**Top K:** 5

**Results Found:** 5

---

## Result 1

**Similarity Score:** 0.3617 | **Semantic:** 0.5168 | **Keyword:** 0.0000 | **Rerank:** -4.7298

**Source:** medires.md

**Chunk ID:** 23

**Content:**

```
sed by Blagoev and Yordanova includes 12 metrics. These metrics are divided into 2 categories namely i) innovation Potential and Capabilities and II) Innovation Activities. The author of the present study has modified the model and have introduced some additional metrics which are Proton Revenues, Revenues Year-Over-Year Growth, R&D expenses Year-Over-Year Growth, R&D intensity Year-Over-Year Growth and total number of employee. In total there are 17 metrics. The modified model is shown in Fig.2.
```

---

## Result 2

**Similarity Score:** 0.3593 | **Semantic:** 0.5020 | **Keyword:** 0.0261 | **Rerank:** -6.5588

**Source:** medires.md

**Chunk ID:** 48

**Content:**

```
l revenues of $2.67 bn and $2.62 bn respectively. In 2021 and 2020 Varian revenue decreased by 52.5% and 2% compared to 2020 and 2019 respectively. Revenue wise Varian stood at third position i.e. has third largest revenues after Hitachi and Siemens Healthineers. Varian revenue increased by 10%, 9.3%, 2% and 5% in 2019, 2018, 2017 and 2016 respectively. Oncology Systems contributed highest revenue by segments of USD 3.0 bn, 3.06 bn, 2.77bn in 2020, 2019 and 2018 respectively.
```

---

## Result 3

**Similarity Score:** 0.3583 | **Semantic:** 0.5119 | **Keyword:** 0.0000 | **Rerank:** -7.9045

**Source:** medires.md

**Chunk ID:** 46

**Content:**

```
tively. Varian segment reported $1.51 bn in 2021. In 2021, highest revenue by region was shown by EMEA (Europe, Common Wealth of Independent States, Africa, Middle East) followed by Americas and Asia & Australia. In 2020 Highest revenue was generated by Americas followed by EMEA and Asia and Australia. The mean, median, maximum and minimum values over a period of six years from 2021- 2016 were $16.75 bn, $15.99 bn, $20.84 bn, and $15.23 bn respectively. These values are significantly higher than IBA, Varian and Accuracy.
```

---

## Result 4

**Similarity Score:** 0.3651 | **Semantic:** 0.5128 | **Keyword:** 0.0204 | **Rerank:** -8.2509

**Source:** pdf-innovative-leadership-comparison-of-ion-beam-applications-sa-belgium-against-its-competitors.md

**Chunk ID:** 37

**Content:**

```
shown in Fig. 3 -1 3 
IBA Revenues and Y-O-Y Growth 
In 
revenue 
2020-2015. towards 
contributions by of
Varian 
therapy segment ge0.18
bn in In
experienced of in
revenue In an
increase of 19.5% 
year. In and PT
decreased by 1.3%, 18.3% 
2016 
revenues to 2016
revenues 
0.38, 0.35 bn in
2018, 2017 and in 2016 respectively. IBA %, 21.6 in
Revenue in to
respective previous
are highest c
IBA 
revenues an of
1.009 
attributed 
Therapy segment. This 
increase in by Other 
0.1bn) and In 2019, IBA experienced 10% in
year. In in
revenues 
2016 respectively.
```

---

## Result 5

**Similarity Score:** 0.3574 | **Semantic:** 0.5106 | **Keyword:** 0.0000 | **Rerank:** -8.8606

**Source:** pdf-innovative-leadership-comparison-of-ion-beam-applications-sa-belgium-against-its-competitors.md

**Chunk ID:** 72

**Content:**

```
on, decline in total revenue 
USD 
systems 
counterbalanced by in
Interventional 
increase in rev
in 
expand into 
revenue 
products 
provide 
features as
patient 
organ 
reduced monitor units, mobile access to patient imaging 
and treatment 
motion 
of data 
and
developmental/production 
compact and cost effective particle therapy
likely to
competitors. By to
reflect 
continue to now of
Healthineers) 
edge. of and to
customers 
Varian edge
However, of
customers to in-house 
engineering and main
```

---

